BMO Capital weighs in on Incyte (INCY) following mCALR antibody data
Tweet Send to a Friend
(Updated - June 3, 2025 12:10 PM EDT)
BMO Capital analyst Evan Seigerman reiterated an Underperform rating and $52.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
BMO Capital analyst Evan Seigerman reiterated an Underperform rating and $52.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
